Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

109.90 +8.03 (+7.88%)

Streaming Delayed Price Updated: 2:04 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform ↗

April 24, 2025

Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China.

Via Benzinga

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

April 24, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

April 22, 2025

From Guardant Health, Inc.

Via Business Wire

RXO, The Ensign Group, LifeStance Health Group, Surgery Partners, and Guardant Health Stocks Trade Down, What You Need To Know

April 21, 2025

A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth....

Via StockStory

3 Reasons to Sell GH and 1 Stock to Buy Instead

April 21, 2025

What a time it’s been for Guardant Health. In the past six months alone, the company’s stock price has increased by a massive 112%, reaching $44.11 per share. This run-up might have investors...

Via StockStory

Topics Bankruptcy

3 of Wall Street’s Favorite Stocks Facing Headwinds

April 18, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗

April 17, 2025

A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Via Investor's Business Daily

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

April 10, 2025

From Guardant Health, Inc.

Via Business Wire

Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH)

April 08, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting...

Via StockStory

Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)

April 03, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.

Via StockStory

3 Small-Cap Stocks in the Doghouse

April 01, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

4 Healthcare Stocks With Massive Gains—and More to Come

March 29, 2025

Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year.

Via MarketBeat

Topics Artificial Intelligence Economy World Trade

The Future of Healthcare: 10 Predictions For The Next Decade

March 27, 2025

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...

Via MarketMinute

Topics Artificial Intelligence

A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack

March 27, 2025

Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.

Via StockStory

Q4 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Impresses

March 26, 2025

Via StockStory

Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries

March 25, 2025

From Guardant Health, Inc.

Via Business Wire

1 Healthcare Stock on Our Watchlist and 2 to Turn Down

March 20, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and...

Via StockStory

Topics Stocks

Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX)

March 14, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst...

Via StockStory

1 Stock Under $50 with Solid Fundamentals and 2 to Turn Down

March 13, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue ↗

March 11, 2025

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.

Via Benzinga

Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday ↗

March 11, 2025

Via Benzinga

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

March 11, 2025

From Guardant Health, Inc.

Via Business Wire

Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled ↗

March 10, 2025

Small caps took another step down this past week as geopolitical events dampened sentiment.

Via Talk Markets

Topics ETFs Stocks / Equities

Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

March 05, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue

March 03, 2025

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 30.2% year on year to $201.8 million. Its GAAP loss of $0.90 per share was 12.4%...

Via StockStory

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2025

From Guardant Health, Inc.

Via Business Wire

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

February 27, 2025

From Guardant Health, Inc.

Via Business Wire

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? ↗

February 21, 2025

Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.

Via Benzinga

Guardant Health Tops Q4 Revenue Forecast ↗

February 20, 2025

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Via The Motley Fool

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

February 20, 2025

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.